. Racial differences in lipid metabolism in women with abdominal obesity. Am J Physiol Regulatory Integrative Comp Physiol 279: R944-R950, 2000.-We evaluated palmitate rate of appearance (R a ) in plasma during basal conditions and during a four-stage epinephrine infusion plus pancreatic hormonal clamp in nine white and nine black women with abdominal obesity, who were matched on fat-free mass, total and percent body fat, and waist-to-hip circumference ratio. On the basis of singleslice magnetic resonance imaging analysis, black women had the same amount of subcutaneous abdominal fat but less intra-abdominal fat than white women (68 Ϯ 9 vs. 170 Ϯ 14 cm 2 , P Ͻ 0.05). Basal palmitate R a was lower in black than in white women (1.95 Ϯ 0.26 vs. 2.88 Ϯ 0.23 mol ⅐ kg fat-free mass Ϫ1 ⅐ min
, P Ͻ 0.05). Basal palmitate R a was lower in black than in white women (1.95 Ϯ 0.26 vs. 2.88 Ϯ 0.23 mol ⅐ kg fat-free mass Ϫ1 ⅐ min
Ϫ1
, P Ͻ 0.005), even though plasma insulin and catecholamine concentrations were the same in both groups. Palmitate R a across a physiological range of plasma epinephrine concentrations remained lower in black women, because the increase in palmitate R a during epinephrine infusion was the same in both groups. We conclude that basal and epinephrine-stimulated palmitate R a is lower in black than in white women with abdominal obesity. The differences in basal palmitate kinetics are not caused by alterations in plasma insulin or catecholamine concentrations or lipolytic sensitivity to epinephrine. The lower rate of whole body fatty acid flux and smaller intra-abdominal fat mass may have clinical benefits because of the relationship between excessive fatty acid availability and metabolic diseases. fatty acid; lipolysis; catecholamine; adipose tissue; stable isotopes THE PREVALENCE OF OBESITY, defined as body mass index (BMI) Ն30 kg/m 2 , in the United States is much higher in black (African-American) than in white (Caucasian) women (12) . However, the mortality rate associated with obesity is lower in black than in white women (7) . Moreover, the prevalence of some of the cardiovascular disease risk factors associated with abdominal obesity (impaired glucose tolerance and dyslipidemia) is lower in abdominally obese black women than in white women when both groups are matched on BMI, percent body fat, and waist-to-hip ratio or waist circumference (3, 8, 10) . The mechanism(s) responsible for the differences in metabolic abnormalities between black and white women with abdominal obesity is not known. It has been hypothesized that increased fatty acid release from visceral/intra-abdominal (4) and subcutaneous fat (18) is responsible for many of the metabolic complications associated with abdominal obesity because of fatty acid effects on hepatic glucose production, insulin-mediated glucose uptake, and very-low-density lipoprotein (VLDL) production (13) . Therefore, it is possible that racial differences in lipolytic sensitivity to insulin or epinephrine, the major plasma hormones that regulate fatty acid release from adipose tissue, contribute to the metabolic differences observed between black and white obese women. Although it has been shown that the antilipolytic effect of insulin in vitro is greater in abdominal subcutaneous adipocytes obtained from black than from white women with abdominal obesity (9), the same research group recently found that the suppressive effect of insulin on fatty acid rate of appearance (R a ) in plasma in vivo was similar in black and white obese women (2) . These results make it unlikely that differences in insulinmediated fatty acid metabolism are responsible for the metabolic differences between groups. However, the effect of race on the sensitivity of fatty acid kinetics to epinephrine has not been investigated.
The purpose of the present study was to evaluate whole body fatty acid kinetics in response to a physiological range of plasma epinephrine concentrations in black and white women with abdominal obesity, matched for age, BMI, percent body fat, fat-free mass (FFM), and waist-to-hip circumference ratio. The pancreatic hormonal clamp technique (19) was used to minimize differences in plasma insulin concentration between groups and prevent the confounding influence of epinephrine-stimulated insulin secretion (14) .
METHODS

Subjects.
Eighteen premenopausal women (9 black and 9 white) with abdominal obesity (BMI 32-40 kg/m 2 , Ͼ40% body wt as fat, waist-to-hip circumference ratio Ն0.85), matched on age, BMI, percent body fat, FFM, and waist-tohip circumference ratio, participated in the study (Table 1) . All subjects completed a comprehensive medical examination, including history and physical examination, electrocardiogram, standard blood and urine tests, and an oral glucose tolerance test. All subjects had normal glucose tolerance, and none had evidence of illness. The subjects were not engaged in regular physical activity. The study was approved by the Human Studies Committee and the General Clinical Research Center Scientific Advisory Committee of Washington University School of Medicine, and written informed consent was obtained from all volunteers before their participation.
Body composition. Total body fat mass (FM) and FFM were determined by dual-energy X-ray absorptiometry (QDR 1000/w, Hologic, Waltham, MA). Abdominal (subcutaneous and intra-abdominal) adipose tissue was quantified by magnetic resonance imaging (Siemens, Iselin, NJ) (1). A singleslice image at the L 2 -L 3 interspace was analyzed for subcutaneous and intra-abdominal adipose tissue content.
Isotope and hormone infusion study. Subjects were admitted to the General Clinical Research Center on the evening before the isotope and hormone infusion study. At 1900 on the day of admission, subjects received a standard meal (55% carbohydrate, 30% fat, and 15% protein) containing 12 kcal/kg adjusted body weight. Adjusted body weight was calculated as follows: ideal body weight ϩ 0.25(actual body weight Ϫ ideal body weight), where ideal body weight was based on the medium frame of the Metropolitan Life Insurance Company table (24) . A snack comprised of two cans of Ensure (Ross Laboratories, Columbus, OH), containing a total of 500 kcal, 80 g of carbohydrate, 17.6 g of protein, and 12.2 g of fat, was served at 2230 and consumed within 30 min.
On the next morning, after subjects had fasted overnight, three catheters were inserted: one was placed into an antecubital vein to infuse hormones and glucose, the second into the contralateral antecubital vein to infuse palmitate tracer, and the third into a radial artery for blood sampling. Catheters were kept patent with infusions of 0.9% saline solution.
At 0800 (time 0), after withdrawal of a blood sample to measure fasting lipid concentrations and background isotopic enrichment, a 7-h isotope and hormone infusion study ( Fig. 1) ) for 1 h by means of a calibrated syringe pump (Harvard Apparatus, South Natick, MA) to assess basal plasma fatty acid kinetics. At 1 h, a pancreatic hormonal clamp (19) was initiated:
; Novo Nordisk Pharmaceuticals, Princeton, NJ), and recombinant human growth hormone (0.00375 g ⅐ kg FFM Ϫ1 ⅐ min Ϫ1 ; Genentech, San Francisco, CA) were infused continuously for 6 h (from 1 h to 7 h). The rate of insulin infusion during the pancreatic clamp was chosen to eliminate the confounding influence of basal hyperinsulinemia associated with abdominal obesity on the lipolytic response to epinephrine. Plasma glucose concentrations were monitored (Glucose AutoAnalyzer, Beckman Instruments, Fullerton, CA) every 10 min between 1 and 3.5 h, and 20% dextrose was infused as necessary to maintain euglycemia during the baseline period of the hormonal clamp. All subjects achieved euglycemia without dextrose infusion by 2.5 h. Therefore, dextrose was not infused during the last hour of the baseline period of the hormonal clamp or during the remainder of the infusion study. At 2.5 h, the palmitate tracer infusion was restarted and continued throughout the study to assess fatty acid kinetics during the baseline period of the pancreatic hormonal clamp and each stage of epinephrine infusion. At 3.5 h, a four-stage epinephrine infusion protocol was started. Epinephrine (Lederle Laboratories, Chicago, IL), containing ascorbic acid (0.5 mg/ml) to prevent degradation, was infused at 0.00125, 0.005, 0.0125, and 0.025
. Each epinephrine infusion lasted 30 min, separated by a 30-min interval between stages without epinephrine infusion to reestablish basal epinephrine concentrations and basal fatty acid kinetics. Blood sampling. Blood samples were obtained before the beginning of the isotope infusion, every 5 min during the last 15 min of the basal period (4 samples between 45 min and 1 h) and the pancreatic hormonal clamp baseline period (4 samples between 3.25 and 3.5 h), and every 5 min throughout each 30-min epinephrine infusion (6 samples) to determine palmitate kinetics and substrate and hormone concentrations. Samples were collected in prechilled tubes containing EDTA to determine isotope enrichment and fatty acid concentration, reduced glutathione and EGTA to determine plasma catecholamine concentration, and EDTA with Trasylol to determine plasma insulin, C-peptide, and glucagon concentrations. After centrifugation, plasma was collected and stored at Ϫ70°C for subsequent analysis.
Analyses. Plasma catecholamine concentrations were determined radioenzymatically (31) . Plasma insulin (26) and C-peptide (20) concentrations were measured by RIA. Plasma total cholesterol, high-density-lipoprotein (HDL) cholesterol, and triglycerides were determined enzymatically (Roche/Hitachi 747 Analyzer, Roche Diagnostics, Indianapolis, IN) with commercially available kits; low-density-lipoprotein (LDL) cholesterol was calculated as the difference between total and HDL cholesterol. Plasma free fatty acid concentrations were quantified by gas chromatography with heptadecanoic acid as an internal standard (35) .
Plasma palmitate tracer-to-tracee ratio was determined by gas chromatography-mass spectrometry with an MSD 5971 system (Hewlett-Packard, Palo Alto, CA) with a capillary column (27) . Briefly, plasma proteins were precipitated with acetone, and plasma lipids were extracted with hexane. Fatty acids were converted to their methyl esters with iodomethane and isolated by using solid-phase extraction cartridges. Samples were dried in a Speed-Vac concentrator (Savant Instruments, Farmingdale, NY), reconstituted in heptane, and transferred to auto sampler vials for gas chromatography-mass spectrometry analysis. Ions at mass-to-charge ratios 270.2, 271.2 ([1-
13 C]palmitate), and 272.2 ([2,2-2 H 2 ]palmitate), representing the molecular ions of unlabeled and labeled methyl esters, respectively, formed by electron impact ionization, were selectively monitored.
Calculations. Palmitate R a in the basal state and during the baseline period of the pancreatic hormonal clamp were calculated using Steele's equation for steady-state conditions (32) . During steady-state conditions, palmitate R a is equal to palmitate rate of disappearance (R d ). Plasma palmitate tracer-to-tracee ratio and concentration data obtained during each 30-min epinephrine infusion were smoothed by spline fitting (34) , and the non-steady-state equation of Steele (32) was used to calculate palmitate kinetics during each epinephrine stage. The effective volume of distribution of palmitate was estimated to be 40 ml/kg.
Statistical analysis. Student's t-test for independent samples was used to test the significance of differences in basal palmitate kinetics between black and white women. The responses of palmitate R a to epinephrine were evaluated by a two-way (subject group ϫ epinephrine stage) ANOVA for repeated measures. Significant F ratios from ANOVA were followed by Tukey's post hoc analyses to assess the significance of differences in palmitate R a between the black and white groups and between epinephrine stages. An ␣ ϭ 0.05 was considered to be statistically significant. Values are means Ϯ SE.
RESULTS
Plasma hormone concentrations.
Mean plasma epinephrine concentrations were similar in the black and white women during basal conditions and the baseline period of the pancreatic hormonal clamp (Fig. 2A) . Plasma epinephrine concentrations increased progressively during epinephrine infusion at 0.00125, 0.005, 0.0125, and 0.025 g ⅐ kg FFM Ϫ1 ⅐ min Ϫ1 (P Ͻ 0.05) and were the same in both groups. Plasma norepinephrine concentrations were similar in black and white women (average 1.04 Ϯ 0.05 and 0.96 Ϯ 0.05 nmol/l, respectively) throughout the study and were not affected by epinephrine infusion. Mean basal plasma insulin (Fig.  2B ) and C-peptide (Fig. 2C) concentrations were similar in black and white women and decreased by ϳ75% during the pancreatic hormonal clamp in both groups (both P Ͻ 0.05). Mean plasma glucagon concentrations were similar in black and white women during basal conditions (70 Ϯ 8 and 83 Ϯ 13 pg/ml, respectively, P ϭ 0.57) and identical throughout the epinephrine infusions (52 Ϯ 4 and 52 Ϯ 5 pg/ml, respectively).
Plasma lipids. Basal plasma triglyceride, total cholesterol, and LDL cholesterol concentrations were lower in black than in white women (Table 2 ). There was a trend for higher plasma HDL cholesterol concentrations in black than in white women, but this difference was not statistically significant ( Table 2 ). Basal plasma fatty acid concentrations tended to be lower in black than in white women (0.41 Ϯ 0.05 vs. 0.50 Ϯ 0.04 mmol/l), but the difference between groups was not statistically significant (P ϭ 0.09). Plasma fatty acid concentrations increased significantly (P Ͻ 0.05) during the baseline period of the pancreatic hormonal clamp in black and white women (to 1.02 Ϯ 0.08 and 1.11 Ϯ 0.06 mmol/l, respectively, P ϭ 0.29 between groups) but did not increase further with epinephrine infusion and were similar in black and white women (1.07 Ϯ 0.09 and 1.21 Ϯ 0.08 mmol/l, respectively, P ϭ 0.13) during the epinephrine infusions.
Fatty acid kinetics. Basal palmitate R a (and R d ), expressed relative to FM or FFM, was ϳ25% lower in our black than our white women (P Ͻ 0.05; Fig. 3 ). Palmitate R a increased during the baseline period of the hormonal clamp in both groups. Although there was a trend toward an increase in palmitate R a during each stage of epinephrine infusion, the increase was not significantly different from the baseline period during any of the four stages because of the large variability in R a values (Fig. 4) . The differences in palmitate R a between black and white women persisted across all stages of epinephrine infusion. However, the relative and absolute increases in palmitate R a from basal values were the same in the two groups (Fig. 5) .
DISCUSSION
Although the prevalence of obesity is greater in black than in white women, black women have a lower risk of developing some of the metabolic complications associated with obesity when both groups are matched on BMI, body fat, and waist circumference or waist-to-hip circumference ratio (3, 8, 10) . We hypothesized that the differences in metabolic abnormalities between groups may be related to racial differences in the regulation of fatty acid metabolism. Therefore, we evaluated basal fatty acid R a and the sensitivity of fatty acid kinetics to epinephrine, the major plasma hormone that stimulates lipolysis, in black and white women with abdominal obesity. A palmitate tracer infusion, in conjunction with a pancreatic hormonal clamp, was used to assess fatty acid kinetics across a physiological range of plasma epinephrine concentrations without the confounding influence of epinephrine-stimulated insulin secretion (14) . Our results demonstrate that basal fatty acid kinetics were lower in obese black than in obese white women matched for percent body fat and waistto-hip circumference ratio. However, the sensitivity of fatty acid mobilization in response to epinephrine infusion was the same in both groups.
We previously found that whole body lipolytic sensitivity to epinephrine is blunted in white women with Values are means Ϯ SE in mg/dl. LDL, low-density lipoprotein; HDL, high-density lipoprotein. P value represents comparison between black and white women. abdominal obesity compared with lean white women (17) . The results from the present study demonstrate that obese black women are just as insensitive to the lipolytic effects of epinephrine as obese white women. The precise mechanism responsible for the blunted response is not known but may be related to a decrease in subcutaneous abdominal adipocyte ␤ 2 -adrenergic receptor density observed in women with abdominal obesity (28). In fact, the blunted lipolytic response to epinephrine in abdominally obese white women in vivo is specific to abdominal, rather than femoral, subcutaneous adipose tissue (17) . Although we assume that the lower whole body lipolytic sensitivity in our black women also was caused by a decreased response to epinephrine in upper-body fat, we did not evaluate regional lipolytic activity in our study subjects. It is possible that the stimulation of lipolysis caused by the decrease in plasma insulin concentration during the pancreatic hormonal clamp blunted the lipolytic effect of epinephrine in our subjects. However, lipolytic rates per unit of FM during epinephrine infusion were much lower in our obese subjects than in lean subjects (17) , suggesting that our obese subjects had additional capacity for lipolysis. Furthermore, the decline in plasma insulin concentrations during the pancreatic clamp was similar in black and white women and, therefore, should not have affected our comparison between the two groups.
The rate of fatty acid release into plasma during basal conditions was lower in our black than in our white subjects. In contrast, Albu et al. (2) found similar values for basal fatty acid R a in black and white women matched for adiposity. However, basal glycerol R a , which provides another index of lipolysis, was lower in their black than in their white subjects. It is unlikely that differences in the concentration of or sensitivity to the major plasma hormones that regulate lipolysis (i.e., insulin and epinephrine) were responsible for the racial difference in basal fat metabolism observed in the present study. Basal plasma insulin and epinephrine concentrations were the same in the two groups. Furthermore, results from the present study, in conjunction with those reported by Albu et al., demonstrate that the sensitivity of fatty acid kinetics to inhibition by insulin and stimulation by epinephrine is the same in black and white obese women. It is possible that racial differences in body fat distribution contributed to the differences in basal fatty acid R a . Although total body FM, percent body weight as fat, waist-to-hip circumference ratio, and waist circumference were similar in our black and white groups, intra-abdominal FM in our black subjects was one-half that of our white subjects. Fatty acids released from intra-abdominal fat that are not cleared by the liver enter the systemic circulation and are detected by a systemic fatty acid tracer infusion. Fatty acids released from a larger intra-abdominal FM in our white subjects may have contributed to their higher fatty acid R a values. However, it seems unlikely that the difference in intraabdominal FM alone was large enough to completely explain the observed differences in systemic fatty acid R a , because only 15% of systemic fatty acid flux in obese persons is derived from splanchnic fatty acids (16, 23) . Therefore, the differences we observed in basal fatty acid kinetics between our black and white women were likely due to differences in lipolysis of subcutaneous adipose tissue triglycerides, involving other lipolytic regulatory mechanisms, such as sympathetic nervous system activity (5), cortisol secretion (29), or local adenosine (30) or cytokine (15) production.
The lower rate of whole body fatty acid R a and R d during basal and epinephrine-stimulated conditions and the smaller amount of visceral/intra-abdominal FM observed in our black than in our white subjects may have considerable clinical benefits and may help explain differences in the prevalence of metabolic abnormalities between black and white obese women. Increased fatty acid release from visceral/intra-abdominal (4) and subcutaneous (18) fat may be responsible for many of the metabolic complications associated with abdominal obesity, such as insulin resistance, hyperglycemia, and dyslipidemia (13) . Excessive release of fatty acids from adipose tissue can impair insulin's ability to suppress hepatic glucose production (11, 25) and decrease insulin-mediated glucose uptake (6, 11, 33) . Furthermore, increased delivery of fatty acids to the liver can increase hepatic VLDL production and plasma lipoprotein concentrations (21) . In concert with previous studies (2, 3, 8, 10, 22) , we found lower plasma triglyceride, total cholesterol, and LDL cholesterol concentrations and a trend toward higher plasma HDL cholesterol concentrations in our black subjects than in our white subjects.
In summary, we found that black women with abdominal obesity had lower basal rates of fatty acid release into plasma and tissue uptake from plasma than white women who were matched on FFM, total body FM, percent body weight as fat, and waist-to-hip circumference ratio. Whole body lipolytic sensitivity to epinephrine, determined by the increase in fatty acid R a during epinephrine infusion, was the same in the two groups. However, fatty acid R a across a physiological range of plasma epinephrine concentrations remained lower in black than in white women because of the differences in basal fatty acid kinetics. The lower rate of fatty acid flux in black women may have important clinical benefits because of the relationship between excessive fatty acid release and metabolic diseases.
Perspectives
Obesity is a major public health problem in the United States and other industrialized countries because of its increasing prevalence, association with serious medical diseases, and considerable economic impact. In addition to percent body fat, the location of excess body fat is also an important risk factor for medical complications. Persons with abdominal (upper body) obesity are at increased risk for insulin resistance, diabetes, hypertension, dyslipidemia, and ischemic heart disease than are those with gluteal/femoral (lower body) obesity. It is likely that increased fatty acid release from intra-abdominal and subcutaneous fat in persons with abdominal obesity contributes to many of their metabolic complications because of the effects of fatty acid uptake on hepatic glucose and VLDL production and skeletal muscle insulin-mediated glucose uptake. However, the prevalence of some of these metabolic abnormalities is lower in black than in white women with abdominal obesity when both groups are matched on BMI, percent body fat, and waist-to-hip ratio or waist circumference. The results of the present study suggest that differences in metabolic abnormalities between groups may be related to racial differences in the regulation of fatty acid metabolism. The lower rate of whole body fatty acid R a and R d during basal and epinephrine-stimulated conditions and the smaller amount of visceral/intra-abdominal FM observed in our black than in our white subjects may have important clinical benefits and may be responsible for some of the differences in the prevalence of metabolic abnormalities between black and white obese women.
